Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
08/2003
08/07/2003US20030148981 Administering a therapeutic formulation containing the phosphorothioate oligonucleotide and at least one cyclodextrin to the mammal; monitoring the immune response of mammal
08/07/2003US20030148945 Antimicrobial and anti-inflammatory peptides
08/07/2003US20030148938 Aqueous sustained-release formulations of proteins
08/07/2003US20030148931 A drug delivery system (DDS) compound of a carboxylated polysaccharide derivative bonded to a camptothecin derivative with or with out a oligopeptide a spacer; storage stability; preservation; side effect reduction; antitumor agents
08/07/2003US20030148928 Enzymatic nucleic acid peptide conjugates
08/07/2003US20030148927 Stable solutions of peptide copper complexes and cosmetic and pharmaceutical formulations produced therefrom
08/07/2003US20030148925 Insulin formulation for inhalation
08/07/2003US20030148511 Induction of immunity using inhibitors of granzymes
08/07/2003US20030148408 Compositions and methods for the diagnosis and treatment of tumor
08/07/2003US20030148347 Nuclear protein
08/07/2003US20030148099 Microcapsules having high carotenoid content
08/07/2003US20030147970 Substantially non-colloidal solution made by combining ingredients comprising (a) water; (b) a source of free silver ions; and (c) a substantially non-toxic, substantially thiol-free, substantially water-soluble complexing agent.
08/07/2003US20030147967 Apparatus and method for preparing microparticles
08/07/2003US20030147966 Nanoparticle delivery vehicle
08/07/2003US20030147962 A lipid or other hydrophobic or amphiphilic compound is integrated into a polymeric matrix for drug delivery to alter drug release kinetics. In embodiments where the drug is water soluble, the drug is released over longer periods of time as
08/07/2003US20030147959 Alpha-tocopherol, stabilized by biocompatible surfactants, as a vehicle or carrier for therapeutic drugs, which is substantially ethanol free and which can be administered to animals or humans various routes is disclosed. Polyoxyethylene
08/07/2003US20030147958 Biodegradable multi-block copolymers of poly(amino acid)s and poly(ethylene glycol) for the delivery of bioactive agents
08/07/2003US20030147955 Dry .1 to 1.5% tamsulosin active material and excipients; treating benign prostatic hyperplasia
08/07/2003US20030147954 Cyclosporin and a release modifier encapsulated in a biodegradable polymer
08/07/2003US20030147952 Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs
08/07/2003US20030147951 Tablet composition
08/07/2003US20030147950 .1-10 mg of tamsulosin with an enteric coating and has a dissolution profile in media of </= 60% at 2 hours; reduced or no food effect
08/07/2003US20030147948 Composition comprises sustained-release fine particles and manufacturing method thereof
08/07/2003US20030147947 Orodispersible solid pharmaceutical form
08/07/2003US20030147943 Topical and transdermal administration of peptidyl drugs using hydroxide releasing agents as permeation enhancers
08/07/2003US20030147942 Pharmaceutical gel composition
08/07/2003US20030147929 Cosmetic agent
08/07/2003US20030147927 Eutectic-based self-nanoemulsified drug delivery system
08/07/2003US20030147926 Compositions and methods for transdermal oxybutynin therapy
08/07/2003US20030147921 Covalently bonding a drug such as captopril to a biopolymeric delivery vehicle such as amino-dextrans, and conjugating the prodrug to a botulinum neurotoxin heavy chain; possible treatment for biological warfare exposure of the toxin
08/07/2003US20030147902 Method of stimulating and immune response by administration of host organisms that express intimin alone of as a fusion protein with one of more other antigens
08/07/2003US20030147898 Adjuvant formulation comprising a submicron oil droplet emulson
08/07/2003US20030147885 Administration of immunologically active mouse/human chimeric anti-CD20 antibodies, radiolabeled anti-CD20 antibodies for treating B cell lymphoma
08/07/2003US20030147881 Directed against a target antigen, cell culture to express, code the protein, for treating cancer
08/07/2003US20030147874 A targeted beta-lactamase enzyme can converting a prodrug to a drug product; used as antiproliferative disorder, anticarcinogenic agent treating cancer, treating autoimmune disease or infectious diseases
08/07/2003US20030147844 A water soluble polymer conjugated drug containing mercaptan group; controlled pharmacokinetics and improved bioavailability, relative to unmodified bioactive materials
08/07/2003US20030147835 Process for the manufacture of hydrogel compositions and hydrogel compositions manufactured thereby
08/07/2003US20030147814 Medicinal aerosol formulations comprising ion pair complexes
08/07/2003US20030147809 Antitumor agents
08/07/2003US20030147808 Single Chain Fv constructs of anti-ganglioside GD2 antibodies
08/07/2003US20030147807 Water soluble paclitaxel derivatives
08/07/2003US20030147806 PSCA: prostate stem cell anitgen and uses thereof
08/07/2003US20030146530 Zero order release and temperature-controlled microcapsules and process for the preparation thereof
08/07/2003CA2477429A1 Targeted immunogens
08/07/2003CA2474958A1 Method for making homogeneous spray-dried solid amorphous drug dispersions using pressure nozzles
08/07/2003CA2474835A1 Immediate release dosage forms containing solid drug dispersions
08/07/2003CA2474809A1 Dry granulated formulations of azithromycin
08/07/2003CA2474807A1 Transport peptides and uses therefor
08/07/2003CA2474723A1 Bioactive keratin peptides
08/07/2003CA2474711A1 Responsive microgel and methods related thereto
08/07/2003CA2474710A1 Freeze-dried pharmaceutically acceptable inclusion complexes of propofol and cyclodextrin
08/07/2003CA2474690A1 Composition for inhalation
08/07/2003CA2474616A1 Human monoclonal antibodies to prostate specific membrane antigen (psma)
08/07/2003CA2474447A1 Pharmaceutical compositions comprising a solid amorphous dispersion of cholesteryl ester transfer protein inhibitors
08/07/2003CA2474425A1 Osmotic delivery system
08/07/2003CA2474349A1 Ophthalmic compositions including oil-in-water emulsions, and methods for making and using the same
08/07/2003CA2472342A1 Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide
08/07/2003CA2472296A1 Fap-activated anti-tumor compounds
08/07/2003CA2472242A1 Cyclosporin-containing sustained release pharmaceutical composition
08/07/2003CA2472103A1 Transmucosal delivery of proton pump inhibitors
08/07/2003CA2469571A1 Methods for blocking or alleviating staphylococcal nasal colonization by intranasal application of monoclonal antibodies
08/06/2003EP1333036A1 Peg-modified erythropoietin
08/06/2003EP1333033A1 FAP-activated anti-tumor compounds
08/06/2003EP1333023A1 Haptens, immunogens, antibodies and conjugates to ketamine and its metabolites
08/06/2003EP1332764A1 A mucoadhesive thermoresponsive medicament-carrier composition
08/06/2003EP1332755A1 Taxol liposome composition for treatment of cancer and preparation thereof
08/06/2003EP1332227A2 Nucleic acid ligands to the prostate specific membrane antigen
08/06/2003EP1332206A1 Recombinant alpha-l-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
08/06/2003EP1332170A1 Method for producing microspherical crystallites from linear polysaccharides, corresponding microspherical crystallites and the use thereof
08/06/2003EP1332145A1 Process for formulation of antibiotic compounds
08/06/2003EP1331972A2 Pharmaceutical compositions
08/06/2003EP1331960A2 Device and method for the cessation of smoking
08/06/2003EP1331951A2 Orally ingestible baked radiopaque product for testing for dysphagia
08/06/2003EP1331950A1 Methods and compositions for nucleic acid delivery
08/06/2003EP1331948A2 Pharmaceutical composition containing honey for the treatment of wounds
08/06/2003EP1331947A2 Use of citric acid as antimicrobial agent or enhancer or as anticancer agent
08/06/2003EP1331942A2 Immunogen comprising ligand bound hiv envelope protein
08/06/2003EP1331929A1 Transdermal drug delivery system with improved water absorbability and adhesion properties
08/06/2003EP1331928A2 Particle formation methods and their products
08/06/2003EP1331927A1 Topical composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid
08/06/2003EP1331902A2 Improved ophthalmic and contact lens solutions containing forms of vitamin b
08/06/2003EP1200070B1 Ambroxol-containing lozenge
08/06/2003EP1162945B1 Particle based vaccine composition
08/06/2003EP1117440B1 Pharmaceutical compositions containing paclitaxel
08/06/2003EP1105102B8 Pharmaceutical composition for injection based on a pharmaceutically acceptable clopidogrel or ticlopidin salt
08/06/2003EP1098664B1 Conjugates for treating inflammatory disorders and associated tissue damage
08/06/2003EP1087800B1 Implantable medical device having anti-infective and contraceptive properties
08/06/2003EP1077684B1 Effervescent preparations
08/06/2003EP1066027B1 Pharmaceutical composition of topiramate
08/06/2003EP1062952B1 Bubbling enteric preparations
08/06/2003EP1030734B1 Encapsulate of active material in alginate matrix
08/06/2003EP1030655B1 Low temperature coatings
08/06/2003EP1003567B1 TEMPERATURE-CONTROLLED pH-DEPENDANT FORMATION OF IONIC POLYSACCHARIDE GELS
08/06/2003EP0973499B1 Diffusional implantable delivery system
08/06/2003EP0906086B1 Skin wash composition
08/06/2003EP0824353A4 Methods to inhibit acute radiation-induced skin damage
08/06/2003EP0806949B1 New pharmaceutical composition containing trimebutine and preparation process
08/06/2003EP0728018B1 New enzymes and prodrugs for ADEPT
08/06/2003EP0701449B1 Process for the preparation of an oral solid dosage form containing diclofenac
08/06/2003CN1434870A Viral core protein-cationic lipid-nucleic acid-delivery complexes
1 ... 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 ... 1712